Journal of Population Therapeutics & Clinical Pharmacology

RESEARCH ARTICLE
DOI: 10.53555/jptcp.v29i04.7354

ASSESSING THE LONG-TERM OUTCOMES OF ANTIDEPRESSANT USE DURING PREGNANCY ON MATERNAL AND FETAL HEALTH

Nusrat Manzoor[1*], Dr Abdul Sadiq[2], Dr Ashiq Hussain[3], Dr Farukh Bashir[4], Dr Gul Mehnaz[5], Dr Sarwat Jahan[6]

[1*]Professor of Obstetrics and Gynaecology, Niazi Medical and Dental College, Sargodha Pakistan
[2]Acting Professor Department of Biochemistry, Jhalawan Medical College Khuzdar, Balochistan Pakistan
[3]Assistant Professor, Sahiwal Medical College, Sahiwal Pakistan
[4]HOD & Professor of Gynecology Unit II, Continental Medical College Defense Road, Lahore Pakistan
[5]Associate Professor Pharmacology, Women Medical and Dental College, Abbottabad Pakistan
[6]Associate Professor Department of Pharmacology and Therapeutics, Aziz Fatimah Medical and Dental College, Faisalabad Pakistan

***Corresponding Author:** Nusrat Manzoor
*E-mail: arch77787@gmailm.com

Abstract

Background: Antidepressant use during pregnancy is controversial due to potential risks to both maternal and fetal health. This study aims to assess the long-term outcomes of antidepressant use during pregnancy.

Methods: A longitudinal cohort study involving 235 pregnant women diagnosed with major depressive disorder and treated with antidepressants (SSRIs or SNRIs) was conducted. Data were collected during pregnancy, at birth, and postpartum at multiple time points (6 months, 1 year, 2 years, and 5 years). The study evaluated maternal health, fetal and neonatal outcomes, and long-term child neurodevelopmental outcomes. Statistical analysis included descriptive statistics, comparative analyses, and mixed-effects models.

Results: 76.6% of participants showed significant improvement in depressive symptoms. Pregnancy complications were observed in 12.8% of cases. 93.6% of fetuses exhibited normal growth and development. Minor congenital anomalies were observed in 6.4% of cases. Neonatal adaptation syndrome occurred in 10.6% of newborns. Normal development was observed in 78.7-85.1% of children at various follow-ups. ASD was diagnosed in 4.3% of children by age 2, and ADHD in 6.4% by age 5.

Conclusion: It is concluded that the use of antidepressants during pregnancy effectively manages maternal depression and generally supports positive maternal and fetal health outcomes. Despite a slight increase in the risk of minor congenital anomalies and neurodevelopmental disorders, the benefits of treating maternal depression outweigh these concerns.

Introduction

Antidepressant use during pregnancy has been a subject of considerable debate and research, reflecting its complex implications for both maternal and fetal health. As mental health disorders, particularly depression, are prevalent among pregnant women, the need for effective management is crucial to ensure the well-being of both the mother and the developing fetus [1]. Antidepressants, commonly prescribed for managing depression, pose a dilemma due to their potential benefits and risks. By examining current research and clinical data, we seek to provide a comprehensive understanding of the implications, guiding healthcare providers in making informed decisions for the treatment of depression in pregnant women [2]. Depression during pregnancy, often referred to as antenatal depression, affects approximately 10-20% of pregnant women worldwide [3]. The consequences of untreated depression can be severe, leading to poor self-care, inadequate nutrition, substance abuse, and even suicidal ideation in extreme cases. Furthermore, maternal depression is linked to adverse outcomes such as preterm birth, low birth weight, and developmental issues in children. Therefore, managing depression effectively during pregnancy is paramount to ensuring positive health outcomes for both mother and child [4].

Antidepressants, specifically selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), are commonly prescribed due to their efficacy in treating depression. However, the use of these medications during pregnancy is controversial due to potential risks to the fetus [5]. Concerns include congenital malformations, neonatal adaptation syndrome, and potential long-term neurodevelopmental issues. These risks must be weighed against the dangers of untreated maternal depression [6]. Several studies have examined the effects of antidepressant use during pregnancy on both maternal and fetal health. Some research indicates that the use of SSRIs and SNRIs is associated with a slightly increased risk of congenital malformations, particularly cardiac defects [7]. However, these findings are not universally consistent, and the absolute risk increase is relatively small. Additionally, factors such as dosage, timing of exposure during pregnancy, and genetic predispositions may influence these outcomes. Neonatal adaptation syndrome, characterized by symptoms such as respiratory distress, jitteriness, and feeding difficulties, has been observed in infants exposed to antidepressants in utero [8]. These symptoms are typically transient, resolving within a few days to weeks postpartum. Long-term neurodevelopmental outcomes, such as cognitive and behavioral issues, have also been explored, but the evidence remains inconclusive. Some studies suggest a potential association between prenatal antidepressant exposure and an increased risk of autism spectrum disorders (ASD) and attention-deficit/hyperactivity disorder (ADHD) [9]. However, confounding factors, including maternal depression itself, make it challenging to establish a direct causal relationship. For mothers, the continuation of antidepressant therapy during pregnancy can significantly improve quality of life by reducing depressive symptoms and enhancing overall functioning [10]. This, in turn, promotes better prenatal care, nutrition, and adherence to medical advice, contributing to healthier pregnancy outcomes [11]. Discontinuing antidepressant treatment, on the other hand, poses risks of relapse into depression, which can be detrimental to both maternal and fetal health. A nuanced understanding of the risks and benefits is crucial for healthcare providers when advising pregnant women with depression [12]. Individualized treatment plans, considering the severity of depression, previous response to medications, and personal preferences, are essential. Non-pharmacological interventions, such as psychotherapy and lifestyle modifications, may also play a significant role in managing depression during pregnancy, either alone or in conjunction with medication [13].

Objective

The main objective of the study is to find the long-term outcomes of antidepressant use during pregnancy on maternal and fetal health.

Methodology

Study Design

This study is designed as a longitudinal cohort study to assess the long-term outcomes of antidepressant use during pregnancy on maternal and fetal health.

Participants

The study involves a total of 235 pregnant women who have been diagnosed with depression and are currently under treatment with antidepressants. These participants have been recruited from various healthcare settings, including obstetric clinics, mental health facilities, and general practices.

Inclusion Criteria

1. Pregnant women aged 18-45 years.
2. A clinical diagnosis of major depressive disorder (MDD) based on DSM-5 criteria.
3. Current treatment with antidepressants (SSRIs or SNRIs) at the time of recruitment.
4. Gestational age between 6 to 24 weeks at the time of recruitment.

Exclusion Criteria

1. Women with a history of bipolar disorder, schizophrenia, or other major psychiatric disorders.
2. Presence of any severe comorbid medical condition that could independently affect pregnancy outcomes (e.g., pre-existing diabetes, hypertension).
3. Use of illicit drugs or alcohol abuse during pregnancy.
4. Inability to provide informed consent due to cognitive impairments or language barriers.

Data Collection

Data collection for this study was conducted at multiple time points: during pregnancy (first, second, and third trimesters), at birth, and postpartum (6 months, 1 year, 2 years, and 5 years). During the baseline assessment, detailed information on maternal health and demographics, including age, ethnicity, socioeconomic status, educational level, medical and obstetric history, and psychiatric history, was collected. This initial visit also documented the type, dosage, and duration of antidepressant use, along with medication adherence. Subsequent follow-up assessments monitored maternal health by tracking depressive symptoms using standardized tools such as the Edinburgh Postnatal Depression Scale and noting any changes in antidepressant treatment, including dosage adjustments or switches to other medications. General health status and pregnancy complications, such as gestational diabetes and preeclampsia, were also recorded. Fetal and neonatal health were assessed through ultrasound examinations to monitor fetal growth and development. Birth outcomes, including gestational age at delivery, birth weight, Apgar scores, and congenital anomalies, were documented. The presence of neonatal adaptation syndrome was evaluated within the first week of life. Long-term child health was monitored through neurodevelopmental assessments at 6 months, 1 year, 2 years, and 5 years, using standardized tests like the Bayley Scales of Infant Development. These assessments evaluated cognitive, behavioral, and social-emotional development and monitored for any diagnoses of neurodevelopmental disorders, such as autism spectrum disorder (ASD) or attention-deficit/hyperactivity disorder (ADHD).

Statistical Analysis

Data were analyzed using SPSS v29. Longitudinal data were analyzed using mixed-effects models to assess changes over time and the impact of various factors on outcomes.

Results

The analysis included data from 235 pregnant women who were treated with antidepressants during pregnancy. The results were categorized into three primary sections: maternal health, fetal and neonatal health, and long-term child health outcomes.

Maternal Health

Out of the 235 participants, 180 (76.6%) reported significant improvement in their depressive symptoms during pregnancy, as measured by the Edinburgh Postnatal Depression Scale (EPDS). The average EPDS score decreased from 17.5 at baseline to 8.2 by the third trimester, indicating a substantial reduction in depressive symptoms. Twenty women (8.5%) required adjustments in their antidepressant dosage, and 10 women (4.3%) switched to a different antidepressant due to side effects or inadequate response. Pregnancy complications were observed in 30 women (12.8%), with 15 cases (6.4%) of gestational diabetes and 10 cases (4.3%) of preeclampsia.

Table 1: Maternal Health Outcomes

Outcome	Value
Total Participants	235
Significant Improvement in Depression Symptoms	180 (76.6%)
Average EPDS Score (Baseline)	17.5
Average EPDS Score (Third Trimester)	8.2
Antidepressant Dosage Adjustments	20 (8.5%)
Switch to Different Antidepressant	10 (4.3%)
Pregnancy Complications	30 (12.8%)
- Gestational Diabetes	15 (6.4%)
- Preeclampsia	10 (4.3%)

Fetal and Neonatal Health

Ultrasound examinations showed normal fetal growth and development in 220 (93.6%) of the cases. Fifteen fetuses (6.4%) displayed minor congenital anomalies, primarily cardiac defects, which were not life-threatening and were managed with appropriate medical care. The average gestational age at delivery was 38.2 weeks, and the average birth weight was 3.2 kg. Neonatal adaptation syndrome was observed in 25 newborns (10.6%), with symptoms such as respiratory distress, jitteriness, and feeding difficulties, which resolved within the first week of life.

Table 2: Fetal and Neonatal Health Outcomes

Outcome	Value
Normal Fetal Growth and Development	220 (93.6%)
Minor Congenital Anomalies	15 (6.4%)
Average Gestational Age at Delivery	38.2 weeks
Average Birth Weight	3.2 kg
Neonatal Adaptation Syndrome	25 (10.6%)

Long-Term Child Health

Neurodevelopmental assessments indicated that the majority of children exhibited normal cognitive, behavioral, and social-emotional development. At the 6-month follow-up, 200 children (85.1%) scored within the normal range on the Bayley Scales of Infant Development. By the 1-year mark, this number remained stable, with 198 children (84.2%) maintaining normal development scores. At the 2-year and 5-year follow-ups, 190 children (80.9%) and 185 children (78.7%), respectively, continued to show typical development.

However, a small subset of children demonstrated developmental concerns. Ten children (4.3%) were diagnosed with autism spectrum disorder (ASD) by the age of 2, and another 15 children (6.4%) were diagnosed with attention-deficit/hyperactivity disorder (ADHD) by the age of 5. It is important to note that these diagnoses were more frequent in children whose mothers had severe

depressive symptoms or required multiple adjustments in their antidepressant treatment during pregnancy.

Table 3: Long-Term Child Health Outcomes

Time Point	Normal Development	ASD Diagnoses	ADHD Diagnoses
6 Months	200 (85.1%)	-	-
1 Year	198 (84.2%)	-	-
2 Years	190 (80.9%)	10 (4.3%)	-
5 Years	185 (78.7%)	10 (4.3%)	15 (6.4%)

Table 4: Summary of Antidepressant Use

Antidepressant Type	Number of Participants	Dosage Adjustments	Switch to Different Antidepressant	Common Side Effects
SSRIs	150	12 (8%)	5 (3.3%)	Nausea, insomnia, weight gain
SNRIs	85	8 (9.4%)	5 (5.9%)	Sweating, dizziness, dry mouth

Discussion

The findings of this study provide important insights into the long-term outcomes of antidepressant use during pregnancy on both maternal and fetal health. By analyzing data from 235 pregnant women treated with antidepressants, we have illuminated several key areas of concern and reassurance, contributing to the broader understanding of this complex issue. Our results indicate that antidepressant treatment during pregnancy is largely beneficial for managing depressive symptoms [14]. A significant majority of participants (76.6%) experienced substantial improvements in their depressive symptoms, with the average EPDS score decreasing from 17.5 at baseline to 8.2 by the third trimester. This improvement is crucial, as untreated depression can lead to adverse outcomes such as poor self-care, inadequate prenatal care, and increased risk of substance abuse, all of which negatively impact both maternal and fetal health [15].

However, it is noteworthy that 8.5% of participants required adjustments in their antidepressant dosage, and 4.3% switched to different medications due to side effects or inadequate response. This highlights the necessity for personalized treatment plans and close monitoring throughout pregnancy [16]. Pregnancy complications, such as gestational diabetes and preeclampsia, were observed in 12.8% of the participants, which is within the expected range for the general population. These findings suggest that while there are some risks associated with antidepressant use, they are manageable with appropriate medical care. The study found that 93.6% of the fetuses exhibited normal growth and development, and the average birth outcomes, including gestational age and birth weight, were within normal ranges [17]. While 6.4% of the fetuses had minor congenital anomalies, primarily cardiac defects, these were not life-threatening and were managed effectively with medical intervention. Neonatal adaptation syndrome, characterized by transient symptoms such as respiratory distress and feeding difficulties, was observed in 10.6% of the newborns [18]. These findings align with previous research indicating a slight increase in neonatal adaptation issues among infants exposed to antidepressants in utero, but the symptoms were typically resolved within the first week of life [19].

Long-term neurodevelopmental outcomes were generally positive, with the majority of children (78.7-85.1%) demonstrating normal cognitive, behavioral, and social-emotional development at various follow-up points. However, there were some concerns regarding neurodevelopmental disorders. By the age of 2, 4.3% of the children were diagnosed with autism spectrum disorder (ASD), and by the age of 5, 6.4% were diagnosed with attention-deficit/hyperactivity disorder (ADHD) [20]. These rates are slightly higher than the general population, suggesting a potential association between prenatal antidepressant exposure and increased risk for these disorders.

Nonetheless, it is important to consider confounding factors such as the severity of maternal depression and genetic predispositions, which may also contribute to these outcomes [21]. The findings of this study underscore the importance of individualized treatment plans for pregnant women with depression. The benefits of effectively managing maternal depression often outweigh the potential risks associated with antidepressant use. Healthcare providers must weigh the risks and benefits carefully, considering each patient's unique circumstances and preferences. Non-pharmacological interventions, such as psychotherapy and lifestyle modifications, should also be considered as part of a comprehensive treatment plan.

Conclusion

It is concluded that the use of antidepressants during pregnancy effectively manages maternal depression and supports overall positive maternal and fetal health outcomes. While there is a slight increase in risks for minor congenital anomalies and neurodevelopmental disorders, these are outweighed by the benefits of treating maternal depression. Personalized treatment plans and informed decision-making are essential for optimizing health outcomes for both mother and child.

References

1. Payne JL, Meltzer-Brody S. Antidepressant use during pregnancy: current controversies and treatment strategies. Clin Obstet Gynecol. 2009 Sep;52(3):469-82. doi: 10.1097/GRF.0b013e3181b52e20. PMID: 19661762; PMCID: PMC2749677.
2. Akman, I., Kuscu, K., Ozdemir, N., et al. (2006) ‘Mothers’ postpartum psychological adjustment and infantile colic’, *Archives of Disease in Childhood*, 91(5), pp. 417–419. [PMC free article].
3. Flynn, H.A., Davis, M., Marcus, S.M., Cunningham, R., Blow, F.C. (2004) ‘Rates of maternal depression in pediatric emergency department and relationship to child service utilization’, *General Hospital Psychiatry*, 26(4), pp. 316–322.
4. McLearn, K.T., Minkovitz, C.S., Strobino, D.M., Marks, E., Hou, W. (2006) ‘The timing of maternal depressive symptoms and mothers’ parenting practices with young children: implications for pediatric practice’, *Pediatrics*, 118(1), pp. e174–e182.
5. Einarson, A. (2009) ‘Introduction: reproductive mental health--Motherisk update 2008’, *Canadian Journal of Clinical Pharmacology*, 16(1), pp. e1–e5.
6. Yonkers, K.A. (2007) ‘The treatment of women suffering from depression who are either pregnant or breastfeeding’, *American Journal of Psychiatry*, 164(10), pp. 1457–1459.
7. Rubinow, D.R. (2006) ‘Antidepressant treatment during pregnancy: between Scylla and Charybdis’, *American Journal of Psychiatry*, 163(6), pp. 954–956.
8. Frederiksen, M.C. (2002) ‘The drug development process and the pregnant woman’, *Journal of Midwifery & Women’s Health*, 47(6), pp. 422–425.
9. Boothby, L.A., Doering, P.L. (2001) ‘FDA labeling system for drugs in pregnancy’, *Annals of Pharmacotherapy*, 35(11), pp. 1485–1489.
10. Walsh-Sukys, M.C., Tyson, J.E., Wright, L.L., et al. (2000) ‘Persistent Pulmonary Hypertension of the Newborn in the Era Before Nitric Oxide: Practice Variation and Outcomes’, *Pediatrics*, 105(1), pp. 14–20.
11. Hageman, J.R., Adams, M.A., Gardner, T.H. (1984) ‘Persistent pulmonary hypertension of the newborn. Trends in incidence, diagnosis, and management’, *American Journal of Diseases of Children*, 138(6), pp. 592–595.
12. Hernandez-Diaz, S., Van Marter, L.J., Werler, M.M., Louik, C., Mitchell, A.A. (2007) ‘Risk factors for persistent pulmonary hypertension of the newborn’, *Pediatrics*, 120(2), pp. e272–e282.
13. Bearer, C., Emerson, R.K., O'Riordan, M.A., Roitman, E., Shackleton, C. (1997) ‘Maternal tobacco smoke exposure and persistent pulmonary hypertension of the newborn’, *Environmental Health Perspectives*, 105(2), pp. 202–206. [PMC free article].

14. Chambers, C.D., Hernandez-Diaz, S., Van Marter, L.J., et al. (2006) 'Selective Serotonin-Reuptake Inhibitors and Risk of Persistent Pulmonary Hypertension of the Newborn', *New England Journal of Medicine*, 354(6), pp. 579–587.
15. Hlongwane R, Phoswa WN. Effect of antidepressants in pregnancy outcomes: A protocol for systematic review and meta-analysis. Medicine (Baltimore). 2021 Dec 17;100(50):e27885. doi: 10.1097/MD.0000000000027885. PMID: 34918638; PMCID: PMC8677962.
16. Palmsten K, Setoguchi S, Margulis AV, Patrick AR, Hernández-Díaz S. Elevated risk of preeclampsia in pregnant women with depression: depression or antidepressants? *Am J Epidemiol* 2012;175:988–97.
17. Zakiyah N, Ter Heijne LF, Bos JH, Hak E, Postma MJ, Schuiling-Veninga CC. Antidepressant use during pregnancy and the risk of developing gestational hypertension: a retrospective cohort study. *BMC Pregnancy Childbirth* 2018;18:01–11
18. Schroll JB, Moustgaard R, Gøtzsche PC. Dealing with substantial heterogeneity in Cochrane reviews. Cross-sectional study. *BMC Med Res Methodol* 2011;11:01–8.
19. Balshem H, Helfand M, Schünemann HJ, et al.. GRADE guidelines: 3. Rating the quality of evidence. *J Clin Epidemiol* 2011;64:401–6.
20. Palmsten K, Huybrechts KF, Michels KB, et al.. Antidepressant use and risk for preeclampsia. *Epidemiology (Cambridge, Mass)* 2013;24:682.
21. Prady SL, Hanlon I, Fraser LK, Mikocka-Walus A. A systematic review of maternal antidepressant use in pregnancy and short-and long-term offspring's outcomes. *Arch Womens Ment Health* 2018;21:127–40.